Neogen Food Safety Corporation Sells Genomics Business to Zoetis Animal Health

Neogen Corporation, an innovative leader in food safety solutions, recently announced it has entered into a definitive agreement to sell its global genomics business to Zoetis Inc., the world’s leading animal health company, for $160 million, subject to customary closing adjustments.

The planned divestiture, which had been previously announced, was part of the company’s portfolio review strategy to simplify the business and focus on core strategic markets. The transaction is expected to close by the end of the first half of the company’s 2027 fiscal year, subject to regulatory approval and customary closing conditions. The net proceeds from the transaction are expected to be used primarily for debt reduction. The Genomics business generated approximately $90 million in sales during fiscal year 2025.

“This transaction is part of the company’s strategic portfolio review and allows the company to accelerate de-leveraging and improve profitability going forward,” said Mike Nassif, Neogen’s Chief Executive Officer and President. “Furthermore, this deal allows us to focus in areas where the company has the most significant competitive advantage and further leverage our core capabilities in food and animal safety. We are committed to a smooth transition for customers, employees and other stakeholders, and believe the business is well positioned to thrive under Zoetis’ ownership.”

Neogen’s Genomics business (GeneSeek) has been a pioneer in advanced DNA testing for livestock and companion animal industries, leveraging a global presence to deliver highly accurate, data-driven insights that contribute to improved animal performance and health, as well as profitability, in the beef, dairy and other industries. Through the flagship Igenity and GGP portfolio and rapid turnaround times, the business offers returns-focused genomic tools and globally recognized standards in genomic prediction to accelerate herd improvement and enable genomics trait screening. Supported by the Encompass platform for genomic data integration and strategic partnerships advancing DNA-backed traceability, GeneSeek is committed to continued innovation and scientific excellence.

Guggenheim Securities LLC acted as exclusive financial advisor to Neogen on the transaction.